Compare Fox Corp Class A (FOXA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Novo Nordisk A/S — how do they compare? Fox Corp Class A trades at $63.88 (market cap $25.36B), while Novo Nordisk A/S trades at $38.2 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.5× Fox Corp Class A's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Novo Nordisk A/S for 116 Days on average.
| FOXA | NVO | |
|---|---|---|
Market Cap | $25.36B | $165.31B |
Volume | 2,566,954 | 11,432,838 |
Sector | Media | Health |
52-Week High | $76.11 | $63.98 |
52-Week Low | $48.79 | $35.29 |
Typical Hold Time | 34 Days | 116 Days |
Enterprise Value | $28.72B | $179.56B |
Dividend Yield | 0.91% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.70, up 1.0% today, with a bearish technical signal but strong fundamentals including a P/E of 16.55 and net income margin of 9.84%. Recent earnings beats and a consensus analyst price target of $72.00 suggest upside potential, though the pending Roku acquisition faces DOJ scrutiny, adding regulatory risk. Cash flow improved in 2025, but a projected net cash outflow in 2026 warrants monitoring.
The outlook is mixed: solid profitability and analyst support contrast with technical weakness and acquisition uncertainty. Investors may find value if the Roku deal proceeds smoothly, but regulatory delays or integration challenges pose significant downside risks to near-term performance.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
